Use of herpes zoster antivirals fell markedly after the launch of a national vaccination program for people in their 70s, suggesting uptake of the jab has previously been underestimated, researchers say.

The vaccine, Zostavax, was added to the National Immunisation Program (NIP) in November 2016, for patients aged 70, with catch-up offered to those aged 71-79.